Curettage alone not advised for sacral giant cell tumors

Curettage alone not advised for sacral giant cell tumors
For patients with sacral giant cell tumors, curettage alone is not recommended for surgical management, according to a study published online July 16 in The Spine Journal.

(HealthDay) -- For patients with sacral giant cell tumors (GCTs), curettage alone is not recommended for surgical management, according to a study published online July 16 in The Spine Journal.

To develop an optimal for GCTs, Guodong Li, M.D., from the Tongji University School of Medicine in Shanghai, and colleagues reviewed a case series of 32 patients (18 women and 14 men) with sacral GCTs who underwent surgery between August 1996 and August 2008.

The researchers found that the patients underwent either wide resection, marginal resection, marginal resection plus curettage, or curettage alone (two, 11, 12, and seven patients, respectively). The highest and lowest amount of was seen for the curettage and wide resection groups, respectively. During a median of 42 months of follow-up, local was noted in 12 patients, including five of seven in the curettage group. The rate of recurrence was significantly lower in the marginal excision group versus the curettage group (18.2 versus 71.4 percent; P = 0.049). Of all the patients, bladder and bowel dysfunction were seen in five and two patients, respectively, while dysfunction was noted for four patients who underwent marginal resection. The overall and two-year recurrence-free survival was 93.6 and 84.4 percent, respectively.

"Choosing an optimal surgical margin in the treatment of sacral GCTs is of great importance for local recurrence control and sacral preservation," the authors conclude. "Curettage alone should not be used to treat sacral GCTs."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Gender, BMI impact bladder perforation during resection

Apr 17, 2012

(HealthDay) -- For patients with bladder tumors, female gender, low body mass index, and tumor characteristics correlate with the risk of bladder perforation during transurethral resection, according to research ...

Preoperative/neoadjuvant therapy in pancreatic cancer

Apr 20, 2010

In research published this week in PLoS Medicine, Jorg Kleeff from Technische Universitat Munchen, and colleagues suggest that patients with apparently locally non-resectable tumors should be included in neoadjuvant protoc ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.